In a report released yesterday, William Plovanic from Canaccord Genuity reiterated a Buy rating on TransMedics Group, with a price target of $142.00. The company’s shares closed yesterday at $111.71.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Plovanic is a 3-star analyst with an average return of 3.4% and a 45.58% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as Artivion, Insulet, and Tandem Diabetes Care.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TransMedics Group with a $142.20 average price target, implying a 27.29% upside from current levels. In a report released yesterday, Jefferies also initiated coverage with a Buy rating on the stock with a $145.00 price target.
The company has a one-year high of $145.50 and a one-year low of $55.00. Currently, TransMedics Group has an average volume of 1.06M.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is neutral on the stock. Most recently, in August 2025, Waleed H Hassanein, the President & CEO of TMDX bought 16,875.00 shares for a total of $1,982,120.66.
Read More on TMDX:
Disclaimer & DisclosureReport an Issue
- TransMedics initiated with a Buy at Jefferies
- Buy Rating for TransMedics Group: Innovative Organ Care System and Promising Growth Prospects
- TransMedics added to ‘Tactical Underperform’ list at Evercore ISI
- TransMedics Group Acquires Aircraft for Organ Transport
- TransMedics Group: Strong Long-Term Investment Despite Short-Term Sales Fluctuations
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/The%20CrowdStrike%20logo%20on%20an%20office%20building%20by%20bluestork%20via%20Shutterstock.jpg)